Novel Drug-Eluting Coronary Artery Stent Coated With Anti-Platelet-Derived Growth Factor Antibodies Overlaying Extracellular Matrix Proteins With an Outer Coating of Anti-Inflammatory (Calcineurin Inhibitor) and/or Anti-Proliferatives
OwnerRobert L. Bjork, JR.inventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination of agents, including an anti-proliferative agent, an anti-inflammatory agent, an anti-growth factor, and an extracellular matrix (ECM) molecule coated on a stent to prevent acute and subacute thrombosis, enhance endothelial in-growth, and prevent neointimal hyperplasia, and/or suppress neovascularization, and thereby reduce restenosis rates for drug eluting stents. The present invention also relates to methods of using such multiple drug eluting stents for the treatment of heart disease and other vascular conditions.
Claims49
A tubular vascular implant comprising;
- a) a first outer layer coating comprising an anti-proliferative agent and an anti-inflammatory agent;
- b) a second middle layer coating comprising at least one anti-growth factor agent;
- and
- c) a third bottom layer coating comprising at least one non-thrombogenic extracellular matrix (ntECM) molecule;
- wherein the first outer layer coating is formulated for immediate and sustained release of the anti-proliferative agent and the anti-inflammatory agent upon implantation and the second middle layer coating is formulated for delayed and sustained release of the at least one anti-growth factor agent, and wherein the at least one ntECM molecule is permanently affixed to the lumen or interstices of the implant.
A tubular vascular implant comprising;
- a) a first outer layer coating comprising paclitaxel and sirolimus;
- and
- b) a second middle layer coating comprising at least one anti-growth factor agent,
- wherein the first outer layer coating is formulated for immediate and sustained release of the paclitaxel and sirolimus upon implantation and the second middle layer coating is formulated for delayed and sustained release of the at least one anti-growth factor agent.
A method of preventing target lesion restenosis (TLR) or target vessel restenosis (TVR) in a subject with clogged heart arteries comprising inserting a tubular vascular implant, wherein the implant comprises:
- a) a first outer layer coating comprising an anti-proliferative agent and an anti-inflammatory agent;
- b) a second middle layer coating comprising at least one anti-growth factor agent;
- and
- c) a third bottom layer coating comprising at least one non-thrombogenic extracellular matrix molecule (ntECM);
- wherein the first outer layer coating is formulated for immediate release of the anti-proliferative agent and the anti-inflammatory agent upon implantation and the second middle layer coating is formulated for delayed release of the at least one anti-growth factor agent, and wherein the at least one ntECM molecule is permanently affixed to the lumen or interstices of the implant.
Dependencies are inferred from the claim text.